Pioglitazone News and Research

RSS
Thiazolidinediones - diabetes drugs carry significant cardiovascular risks

Thiazolidinediones - diabetes drugs carry significant cardiovascular risks

Thiazolidinediones may slow bone formation and speed bone loss

Thiazolidinediones may slow bone formation and speed bone loss

Study shows Actos prevented progression of atherosclerotic plaque volume in patients

Study shows Actos prevented progression of atherosclerotic plaque volume in patients

New understanding of the link between heart disease and belly fat

New understanding of the link between heart disease and belly fat

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Use of thiazolidinediones by seniors linked with increased risk of heart problems

Use of thiazolidinediones by seniors linked with increased risk of heart problems

Anti-diabetic drug pioglitazone lowers cardiovascular risk in diabetic patients with kidney disease

Anti-diabetic drug pioglitazone lowers cardiovascular risk in diabetic patients with kidney disease

Study finds Avandia may increase risk of heart failure

Study finds Avandia may increase risk of heart failure

GlaxoSmithKline response to JAMA article on ICES retrospective analysis

GlaxoSmithKline response to JAMA article on ICES retrospective analysis

MIT researchers devised novel way to create tiny colonies of living human liver cells that model full-sized organs

MIT researchers devised novel way to create tiny colonies of living human liver cells that model full-sized organs

Rosiglitazone and Pioglitazone increase risk of congestive heart failure but not the risk of cardiovascular death

Rosiglitazone and Pioglitazone increase risk of congestive heart failure but not the risk of cardiovascular death

ACTOS associated with reduced risk of heart attack and stroke in patients with type 2 diabetes

ACTOS associated with reduced risk of heart attack and stroke in patients with type 2 diabetes

Glycemic control medication appears to have favorable effect regarding risk of cardiovascular events

Glycemic control medication appears to have favorable effect regarding risk of cardiovascular events

GlaxoSmithKline responds to Journal of the American Medical Association articles

GlaxoSmithKline responds to Journal of the American Medical Association articles

Diabetes drug Pioglitazone reduces risk of death, heart attack and stroke, but increases risk of heart failure

Diabetes drug Pioglitazone reduces risk of death, heart attack and stroke, but increases risk of heart failure

Strengthened warnings on some type 2 diabetes drugs

Strengthened warnings on some type 2 diabetes drugs

FDA Avandia recommendation welcomed by Endocrinologists

FDA Avandia recommendation welcomed by Endocrinologists

Takeda responds to FDA recommendation on Actos

Takeda responds to FDA recommendation on Actos

Avandia too risky says expert

Avandia too risky says expert

Metformin gets top grade for diabetes

Metformin gets top grade for diabetes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.